MCID: NRN001
MIFTS: 47

Neuroendocrine Carcinoma

Categories: Cancer diseases, Endocrine diseases, Neuronal diseases

Aliases & Classifications for Neuroendocrine Carcinoma

MalaCards integrated aliases for Neuroendocrine Carcinoma:

Name: Neuroendocrine Carcinoma 12 15
Carcinoma, Neuroendocrine 43
Carcinoma Neuroendocrine 54
Neuroendocrine Cancer 74

Classifications:



External Ids:

Disease Ontology 12 DOID:1800
MeSH 43 D018278
NCIt 49 C3773
SNOMED-CT 67 253000007
UMLS 71 C0206695

Summaries for Neuroendocrine Carcinoma

Disease Ontology : 12 A carcinoma that derives from neuroendocrine cells.

MalaCards based summary : Neuroendocrine Carcinoma, also known as carcinoma, neuroendocrine, is related to pulmonary large cell neuroendocrine carcinoma and cervical large cell neuroendocrine carcinoma. An important gene associated with Neuroendocrine Carcinoma is SYP (Synaptophysin), and among its related pathways/superpathways are Neuroscience and Central carbon metabolism in cancer. The drugs Everolimus and Octreotide have been mentioned in the context of this disorder. Affiliated tissues include lung, thyroid and breast, and related phenotypes are cellular and nervous system

Wikipedia : 74 Neuroendocrine tumors (NETs) are neoplasms that arise from cells of the endocrine (hormonal) and nervous... more...

Related Diseases for Neuroendocrine Carcinoma

Diseases related to Neuroendocrine Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 873)
# Related Disease Score Top Affiliating Genes
1 pulmonary large cell neuroendocrine carcinoma 34.7 SYP NCAM1 CHGA
2 cervical large cell neuroendocrine carcinoma 34.6 SYP CHGA
3 primary hepatic neuroendocrine carcinoma 34.5 SYP CHGA
4 ovarian large-cell neuroendocrine carcinoma 33.9 SYP NCAM1 KRT7 KRT20 ENO2 CHGA
5 urinary bladder small cell neuroendocrine carcinoma 33.6 SYP NCAM1 KRT7 KRT20 GRP ENO2
6 large cell neuroendocrine carcinoma 33.1 SYP PDGFRA NKX2-1 NCAM1 KRT7 KRT20
7 small cell carcinoma of the bladder 32.8 SYP NKX2-1 KRT7 KRT20 ENO2 CHGA
8 pancreatic endocrine carcinoma 32.7 SYP SST NCAM1 GAST CHGA
9 gallbladder small cell carcinoma 32.2 SYP NCAM1 KRT7 ENO2 CHGA
10 merkel cell carcinoma 32.0 SYP SST PAX5 NKX2-1 NCAM1 MUC1
11 rare tumor 31.5 SST KIT
12 adenocarcinoma 31.2 PTEN NKX2-1 MUC1 KRT7 KRT20 KIT
13 squamous cell carcinoma 31.1 PTEN MUC1 KRT7 KRT19 FGFR4
14 cervix small cell carcinoma 31.0 SYP ENO2 CHGA
15 olfactory neuroblastoma 31.0 SYP NKX2-1 ENO2 CHGA
16 thyroid carcinoma 31.0 PTEN NKX2-1 CALCA
17 sinonasal undifferentiated carcinoma 31.0 SYP MUC1 ENO2
18 appendix adenocarcinoma 31.0 SYP KRT7 KRT20 CHGA
19 breast neuroendocrine neoplasm 30.9 SYP ENO2 CHGA
20 carcinosarcoma 30.9 PTEN MUC1 KRT7 KIT
21 villous adenoma 30.9 SST MUC1 KRT20
22 adenoma 30.8 SYP SST MUC1 KRT7 KRT20 CHGA
23 signet ring cell adenocarcinoma 30.8 MUC1 KRT7 KRT20 CHGA
24 multiple endocrine neoplasia, type i 30.8 SYP SST GAST CHGA
25 skin benign neoplasm 30.8 KRT7 KRT20 ENO2
26 cervical adenocarcinoma 30.8 PTEN KRT7 KRT20
27 eyelid carcinoma 30.8 KRT7 KRT20
28 lung large cell carcinoma 30.7 SYP NKX2-1 NCAM1 CHGA
29 atrophic gastritis 30.7 SST MUC1 GAST CHGA
30 transitional cell carcinoma 30.7 PTEN KRT7 KRT20 KRT19 ENO2
31 carcinoid syndrome 30.7 SYP SST ENO2 CHGA CALCA
32 neurilemmoma 30.6 PDGFRA MUC1 KIT ENO2
33 thyroid gland medullary carcinoma 30.6 SST GAST CHGA CALCA
34 intrahepatic cholangiocarcinoma 30.6 PTEN MUC1 KRT7 KRT20 KRT19
35 ampulla of vater neoplasm 30.5 SYP SST ENO2 CHGA
36 mature teratoma 30.5 SYP KRT7 KIT ENO2
37 endocervical adenocarcinoma 30.5 MUC1 KRT7 KRT20
38 intracranial cysts 30.5 MUC1 ENO2
39 papillary adenocarcinoma 30.5 NKX2-1 MUC1 KRT7 KRT19
40 cholangiocarcinoma 30.5 NCAM1 MUC1 KRT7 KRT20 KRT19
41 eyelid benign neoplasm 30.5 KRT20 CHGA
42 external ear carcinoma 30.5 KRT7 CALCA
43 acinar cell carcinoma 30.5 SYP KRT7 GAST CHGA
44 zollinger-ellison syndrome 30.5 SST GRP GAST CHGA
45 gallbladder cancer 30.5 PTEN MUC1 KRT7 KRT20 KRT19
46 glucagonoma 30.5 SST GAST CHGA
47 spindle cell thymoma 30.4 MUC1 ENO2
48 tubular adenocarcinoma 30.4 SYP NCAM1 MUC1 KRT7 KRT20 ENO2
49 cystitis cystica 30.4 KRT7 KRT20
50 lung oat cell carcinoma 30.4 SYP GRP ENO2 CHGA CALCA

Graphical network of the top 20 diseases related to Neuroendocrine Carcinoma:



Diseases related to Neuroendocrine Carcinoma

Symptoms & Phenotypes for Neuroendocrine Carcinoma

MGI Mouse Phenotypes related to Neuroendocrine Carcinoma:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.11 ASCL1 ENO2 FGFR4 KIT KRT19 KRT7
2 nervous system MP:0003631 10.07 ASCL1 CHGA ENO2 GRP KIT KRT19
3 neoplasm MP:0002006 9.92 FGFR4 GAST KIT KRT19 NKX2-1 PAX5
4 no phenotypic analysis MP:0003012 9.7 ASCL1 CHGA KIT KRT19 NKX2-1 PDGFRA
5 normal MP:0002873 9.61 ASCL1 KIT KRT19 NKX2-1 PAX5 PDGFRA
6 respiratory system MP:0005388 9.28 ASCL1 ENO2 FGFR4 GRP KIT KRT19

Drugs & Therapeutics for Neuroendocrine Carcinoma

Drugs for Neuroendocrine Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 172)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Everolimus Approved Phase 3 159351-69-6 70789204 6442177
2
Octreotide Approved, Investigational Phase 3 83150-76-9 383414 6400441
3 Immunologic Factors Phase 3
4 Immunosuppressive Agents Phase 3
5 Antineoplastic Agents, Hormonal Phase 3
6 Gastrointestinal Agents Phase 3
7
Loperamide Approved Phase 1, Phase 2 53179-11-6 3955
8
Lactitol Approved, Investigational Phase 1, Phase 2 585-88-6, 585-86-4 493591
9
Palbociclib Approved, Investigational Phase 2 571190-30-2 5005498 11431660 5330286
10
Pertuzumab Approved Phase 2 380610-27-5, 145040-37-5 2540
11
Methotrexate Approved Phase 2 59-05-2, 1959-05-2 126941
12
Cyclophosphamide Approved, Investigational Phase 2 50-18-0, 6055-19-2 2907
13
Pasireotide Approved Phase 2 396091-73-9 9941444
14
Melphalan Approved Phase 2 148-82-3 460612 4053
15
Histamine Approved, Investigational Phase 1, Phase 2 51-45-6 774
16
Clotrimazole Approved, Vet_approved Phase 2 23593-75-1 2812
17
Miconazole Approved, Investigational, Vet_approved Phase 2 22916-47-8 4189
18
lanreotide Approved Phase 2 108736-35-2
19
Levoleucovorin Approved, Investigational Phase 2 68538-85-2
20
Somatostatin Approved, Investigational Phase 2 38916-34-6, 51110-01-1 53481605
21
nivolumab Approved Phase 2 946414-94-4
22
Trifluridine Approved, Investigational Phase 2 70-00-8 6256
23
Docetaxel Approved, Investigational Phase 2 114977-28-5 148124
24
Atezolizumab Approved, Investigational Phase 2 1380723-44-3
25
Midazolam Approved, Illicit Phase 1, Phase 2 59467-70-8 4192
26
Prednisone Approved, Vet_approved Phase 2 53-03-2 5865
27
Sirolimus Approved, Investigational Phase 2 53123-88-9 5284616 6436030 46835353
28
Paclitaxel Approved, Vet_approved Phase 2 33069-62-4 36314
29
Sunitinib Approved, Investigational Phase 2 557795-19-4, 341031-54-7 5329102
30
Bevacizumab Approved, Investigational Phase 2 216974-75-3
31
Capecitabine Approved, Investigational Phase 2 154361-50-9 60953
32
Iodine Approved, Investigational Phase 2 7553-56-2 807
33
Salmon calcitonin Approved, Investigational Phase 2 47931-85-1 16129616
34
Nintedanib Approved Phase 2 656247-17-5 56843413
35
Temozolomide Approved, Investigational Phase 2 85622-93-1 5394
36
Ponatinib Approved, Investigational Phase 2 943319-70-8 24826799
37
Parathyroid hormone Approved, Investigational Phase 2 9002-64-6
38
Olaparib Approved Phase 2 763113-22-0 23725625
39
Lenvatinib Approved, Investigational Phase 2 417716-92-8
40
leucovorin Approved Phase 2 58-05-9 6006 143
41
Fluorouracil Approved Phase 2 51-21-8 3385
42
Irinotecan Approved, Investigational Phase 2 97682-44-5, 100286-90-6 60838
43
Pembrolizumab Approved Phase 2 1374853-91-4
44
Carboplatin Approved Phase 1, Phase 2 41575-94-4 10339178 38904 498142
45
Etoposide Approved Phase 2 33419-42-0 36462
46
Cisplatin Approved Phase 2 15663-27-1 2767 441203 84093
47
Lenograstim Approved, Investigational Phase 2 135968-09-1
48
Sargramostim Approved, Investigational Phase 2 83869-56-1, 123774-72-1
49
Pancrelipase Approved, Investigational Phase 2 53608-75-6
50
Oxaliplatin Approved, Investigational Phase 2 61825-94-3 43805 6857599 5310940 9887054

Interventional clinical trials:

(show top 50) (show all 193)
# Name Status NCT ID Phase Drugs
1 The Use of Lu177 in the Treatment of Progressive and Unresectable Metastatic Medullary Thyroid Cancer Unknown status NCT01915485 Phase 4
2 A Randomized, Double-blind Study To Evaluate the Efficacy and Safety of Cabozantinib (XL184) at 60 mg/Day Compared to a 140 mg/Day in Progressive, Metastatic Medullary Thyroid Cancer Patients Recruiting NCT01896479 Phase 4 Cabozantinib (XL184) 140 mg;Cabozantinib (XL184) 60 mg;Placebo tablet;Placebo capsule
3 A Randomized, Double-blind, Placebo-controlled, Multicenter Clinical Trial to Compare the Efficacy and Safety of Anlotinib Versus Placebo in Patients With Medullary Thyroid Carcinoma(ALTER01031) Completed NCT02586350 Phase 2, Phase 3 Anlotinib;Placebo
4 A Randomized, Double-blind Placebo-controlled, Multicenter Phase III Study in Patients With Advanced Carcinoid Tumor Receiving Octreotide Depot and Everolimus 10 mg/Day or Octreotide Depot and Placebo Completed NCT00412061 Phase 3 Octreotide;Placebo;Everolimus
5 Phase II/III Trial of Simmtecan and 5-FU/LV Regimen (FOLFSIM) Plus Teripalimab Versus EP/EC in Advanced or Metastatic Neuroendocrine Carcinoma Recruiting NCT03992911 Phase 2, Phase 3 Simmtecan, 5-FU and l-LV;Toripalimab;Etoposide, Cisplatin;Etoposide, Carboplatin
6 A Multicenter, Randomized, Open-label, Phase 3 Trial Comparing Selpercatinib to Physicians Choice of Cabozantinib or Vandetanib in Patients With Progressive, Advanced, Kinase Inhibitor Naïve, RET-Mutant Medullary Thyroid Cancer (LIBRETTO-531) Recruiting NCT04211337 Phase 3 Selpercatinib;Cabozantinib;Vandetanib
7 An International, Phase III, Randomized, Double-Blinded, Placebo-Controlled, Multi-Center Study to Assess the Efficacy of ZD6474 (ZACTIMATM) Versus Placebo in Subjects With Unresectable Locally Advanced or Metastatic Medullary Thyroid Cancer Active, not recruiting NCT00410761 Phase 3 ZD6474 (Vandetanib)
8 A Randomized,Int.,Open-Label Phase III Study to Assess the Effect of a Patient Outreach Program on the Percentage of Time Patients With Locally Advanced or Metastatic MTC Experience Grade 2 or Higher AEs in the First 12 Months of Treatment With Vandetanib Active, not recruiting NCT01298323 Phase 3 Vandetanib
9 Phase II Study of FOLFIRI as the Seconde Line Chemotherapy in Advanced or Metastatic Neuroendocrine Carcinoma Unknown status NCT03168607 Phase 2 FOLFIRI Protocol
10 Optimization for the Treatment of Advanced Pulmonary Large Cell Neuroendocrine Carcinoma: a Prospective, Randomized, Open-label, Phase 2 Study Unknown status NCT02943798 Phase 2 etoposide plus carboplatin;Paclitaxel plus carboplatin
11 68Ga-DOTATATE PET Scan Imaging in Patients With Neuroendocrine Tumors Unknown status NCT02038738 Phase 1, Phase 2 68Ga-DOTATATE will be given in tracer doses and injected intravenously to image tumors by Positron Emission Tomography.
12 68-Ga-DOTATATE PET-CT Scan for Diagnosis and Staging of Neuroendocrine Tumors Unknown status NCT01879657 Phase 1, Phase 2 68Ga-DOTATATE PET scan
13 Phase II Study of the Combination of Bevacizumab Plus Somatostatin Analogue and Metronomic Capecitabine in Patients With Advanced Inoperable Well-Differentiated Neuroendocrine Tumors Unknown status NCT01203306 Phase 2 bevacizumab + octreotide LAR + capecitabine
14 A Phase II Clinical Trial of Cisplatin + Gemcitabine HCl (GEM) + Low-Dose Metronomic Interferon-a (IFN-a) Combined With Fever-Range Whole-Body Thermal Therapy (FR-WB-TT) in Patients With Metastatic/or Locally Advanced Malignancies (Small-Cell Lung Cancer, Neuroendocrine Cancer, Gastric Cancer) Unknown status NCT00178698 Phase 2 Cisplatin, Gemcitabine, Interferon-a
15 The Efficacy of CASAD in Patients With Diarrhea Related to Medullary Thyroid Cancer Unknown status NCT01739634 Phase 1, Phase 2 CASAD
16 Randomized Phase II Study of Octreotide LAR as Maintenance Treatment After First-line Chemotherapy for Patients With Unresectable or Metastatic Gastro-entero-pancreatic or Esophageal Neuroendocrine Carcinomas Unknown status NCT02409849 Phase 2 Octreotide lar
17 An Open Label, Single-Centre, Pilot Study for Radiosensitization of Everolimus With External Beam Radiotherapy for the Treatment of Metastatic Neuroendocrine Liver Metastasis Unknown status NCT02205515 Phase 1, Phase 2 Everolimus
18 A Phase Ib, Open-label Study to Evaluate RAD001 as Monotherapy Treatment in Chinese Patients With Advanced Pulmonary Neuroendocrine Tumor Unknown status NCT01175096 Phase 1, Phase 2 RAD001 (everolimus, Afinitor®)
19 A Phase 2, Multi-Center, Open Label Study Evaluating the Efficacy and Safety of Quarfloxin in Patients With Low to Intermediate Grade Neuroendocrine Carcinoma Completed NCT00780663 Phase 2 Quarfloxin
20 A Phase 2 Study of GW786034 (Pazopanib) in Advanced Low-Grade or Intermediate-Grade Neuroendocrine Carcinoma Completed NCT00454363 Phase 2 Pazopanib Hydrochloride
21 Use of 68Ga-DOTATATE PET Scanning for Diagnosis and Treatment of Metastatic Neuroendocrine Tumors Completed NCT01396382 Phase 2
22 A Phase II Trial to Assess the Activity and Safety of Palbociclib in Patients With Well and Moderately Differentiated Metastatic Pancreatic Neuroendocrine Tumors (pNET) Completed NCT02806648 Phase 2 Palbociclib
23 An Open Label Phase II Study to Evaluate the Efficacy and Safety of PDR001 in Patients With Advanced or Metastatic, Well-differentiated, Non-functional Neuroendocrine Tumors of Pancreatic, Gastrointestinal (GI), or Thoracic Origin or Poorly-differentiated Gastroenteropancreatic Neuroendocrine Carcinoma (GEP-NEC), That Have Progressed on Prior Treatment. Completed NCT02955069 Phase 2 PDR001
24 Phase II Study of Paclitaxel, Carboplatin, and Oral Etoposide Followed by Weekly Paclitaxel in the Treatment of High Grade Neuroendocrine Carcinoma Completed NCT00193531 Phase 2 Paclitaxel;Carboplatin;Etoposide
25 A Phase II Clinical Trial of Irinotecan (CPT-11) in Patients With Advanced High Grade Neuroendocrine Tumors Completed NCT00004922 Phase 2 irinotecan hydrochloride
26 A Phase II, Open-Label Study To Assess The Efficacy and Tolerability of ZD6474 (ZACTIMA™ ) 100 mg Monotherapy In Subjects With Locally Advanced or Metastatic Hereditary Medullary Thyroid Cancer Completed NCT00358956 Phase 2 ZD6474 (vandetanib)
27 A Pilot Study of Avelumab in Unresectable/Metastatic, Progressive, Poorly Differentiated Grade 3 Neuroendocrine Carcinomas Completed NCT03278405 Phase 1, Phase 2 Avelumab
28 Phase II Study of the Combination of Bevacizumab, Pertuzumab, and Sandostatin for Patients With Advanced Neuroendocrine Cancers. Completed NCT01121939 Phase 2 Bevacizumab;Pertuzumab;Sandostatin LAR® Depot
29 A Phase II Trial of Cyclophosphamide, Methotrexate and 5-Fluorouracil (CMF) in Neuroendocrine Carcinoma of the Skin (Merkel Cell Carcinoma) Completed NCT00003549 Phase 2 CMF regimen;cyclophosphamide;fluorouracil;methotrexate
30 Everolimus and Temozolomide as 1-line Treatment in Advanced Gastroenteropancreatic Neuroendocrine Carcinoma (G3) With a Ki67 of 20-55% Completed NCT02248012 Phase 2 Everolimus , temozolomide
31 Multicenter 3-arm Trial to Evaluate the Efficacy and Safety of Pasireotide LAR or Everolimus Alone or in Combination in Patients With Well Differentiated Neuroendocrine Carcinoma of the Lung and Thymus - LUNA Trial Completed NCT01563354 Phase 2 Pasireotide LAR;Everolimus;Pasireotide LAR + Everolimus
32 An Open Label, Stratified, Single-arm Phase II Study of Everolimus in Patients With Advanced Pancreatic Neuroendocrine Tumor (NET) After Failure of Cytotoxic Chemotherapy Completed NCT00363051 Phase 2 Everolimus 10 mg;Octreotide Depot
33 TheraSphere for the Treatment of Liver Metastases: An Open Label Trial of TheraSphere in Patients With Liver Metastases From Primary Colorectal Cancer, Neuroendocrine Cancer or Non-colorectal/Non-neuroendocrine Cancer Completed NCT00511862 Phase 2
34 A Phase II Trial of STI-571/Imatinib (Gleevec®) (NSC-716051) in Neuroendocrine Carcinoma of the Skin (Merkel Cell Carcinoma) Completed NCT00068783 Phase 2 imatinib mesylate
35 Investigator Initiated, Phase 2 Clinical Trial of Selinexor (KPT-330) for the Treatment of Poorly Differentiated Lung and Gastroenteropancreatic Tumors Completed NCT02250885 Phase 2 Selinexor
36 A Phase II Open-Label Study of the Safety and Efficacy of Atiprimod Treatment for Patients With Low to Intermediate Grade Neuroendocrine Carcinoma Completed NCT00388063 Phase 2 Atiprimod
37 A Phase II Study of Irinotecan and Cisplatin for Metastatic or Unresectable High Grade Neuroendocrine Carcinoma of the Gastrointestinal Tract Completed NCT00353015 Phase 2 Cisplatin;Irinotecan
38 A Phase II Study of G3139 (Genasense ™) in Patients With Merkel Cell Carcinoma Completed NCT00079131 Phase 2
39 A Phase II Open-Label Extension Study of the Safety and Efficacy of Atiprimod Treatment for Patients With Low to Intermediate Grade Neuroendocrine Carcinoma Completed NCT00663429 Phase 2 Atiprimod
40 Investigation of 68Ga-DOTATATE, as a PET Imaging Agent in Neuroendocrine Tumor Patients Completed NCT01873248 Phase 1, Phase 2 68Ga-DOTATATE
41 SAMSUND MEDICAL CENTER Completed NCT03147404 Phase 2 Avelumab
42 Phase II Study of RAD001 Plus Octreotide Depot in Patients With Metastatic or Unresectable Low Grade Neuroendocrine Carcinoma (Carcinoid, Islet Cell) Completed NCT00113360 Phase 2 RAD001;Octreotide Depot
43 A Phase II Study of Isolated Hepatic Perfusion (IHP) With Melphalan for Metastatic Unresectable Cancers of the Liver Completed NCT00019786 Phase 2 isolated perfusion;melphalan
44 Exploratory Study of Avastin (Bevacizumab) and RAD001 (Everolimus) in Advanced Low or Intermediate Grade Neuroendocrine Carcinoma (AVF3961s) (CRAD001C2481) Completed NCT00607113 Phase 2 Avastin;RAD001
45 A Phase II Single Arm Trial Evaluating the Efficacy and Safety of Temozolomide for Second-Line Treatment of Neuroendocrine Carcinomas Progressing After First-Line Platinum- Based Therapy Completed NCT04122911 Phase 2 Temozolomide
46 Phase I and Randomized Phase II Double Blind Clinical Trial of Cisplatin and Etoposide in Combination With Veliparib (ABT-888) or Placebo as Frontline Therapy for Extensive Stage Small Cell Lung Cancer Completed NCT01642251 Phase 1, Phase 2 Cisplatin;Etoposide;Veliparib;Placebo
47 A Phase 2, Multicenter, Two Tier Study of IMC-A12 in Combination With Depot Octreotide in Patients With Metastatic, Well or Moderately Differentiated Carcinoid or Islet Cell Carcinoma Completed NCT00781911 Phase 2 depot octreotide
48 A Phase 1/2 Dose Escalation Study to Determine the Safety, Pharmacokinetics, and Pharmacodynamics of Intravenous TKM-080301 in Patients With Advanced Solid Tumors Completed NCT01262235 Phase 1, Phase 2 TKM-080301
49 A Phase I/II, Open-label Study to Evaluate the Safety and Tolerability of Vandetanib 300 mg/Day in Japanese Patients With Unresectable Locally Advanced or Metastatic Medullary Thyroid Carcinoma Completed NCT01661179 Phase 1, Phase 2 Vandetanib 300mg
50 A Phase II Study of GW 786034 (Pazopanib) in Advanced Thyroid Cancer Completed NCT00625846 Phase 2 Pazopanib Hydrochloride

Search NIH Clinical Center for Neuroendocrine Carcinoma

Cochrane evidence based reviews: carcinoma, neuroendocrine

Genetic Tests for Neuroendocrine Carcinoma

Anatomical Context for Neuroendocrine Carcinoma

MalaCards organs/tissues related to Neuroendocrine Carcinoma:

40
Lung, Thyroid, Breast, Cervix, Liver, Prostate, Skin

Publications for Neuroendocrine Carcinoma

Articles related to Neuroendocrine Carcinoma:

(show top 50) (show all 4244)
# Title Authors PMID Year
1
Large cell neuroendocrine carcinoma with sarcomatous changes of the endometrium: a case report with immunohistochemical studies and molecular genetic study of KIT and PDGFRA. 54 61
20189318 2010
2
An immunohistochemical study of cervical neuroendocrine carcinomas: Neoplasms that are commonly TTF1 positive and which may express CK20 and P63. 61 54
20182342 2010
3
Significant high expression of cytokeratins 7, 8, 18, 19 in pulmonary large cell neuroendocrine carcinomas, compared to small cell lung carcinomas. 54 61
20398190 2010
4
Reclassifying bronchial-pulmonary carcinoma: differentiating histological type in biopsies by immunohistochemistry. 61 54
19859629 2009
5
The expression and diagnostic utility of p63 in the female genital tract. 54 61
19700941 2009
6
Expression of Notch-1 and alteration of the E-cadherin/beta-catenin cell adhesion complex are observed in primary cutaneous neuroendocrine carcinoma (Merkel cell carcinoma). 61 54
19396152 2009
7
A limited immunohistochemical panel helps differentiate small cell epithelial malignancies of the sinonasal cavity and nasopharynx. 61 54
19077909 2009
8
Immunohistochemical expression of somatostatin type 2A receptor in neuroendocrine carcinoma of uterine cervix. 54 61
18726606 2009
9
Cutaneous metastasis from large-cell neuroendocrine carcinoma of the urinary bladder expressing CK20 and TTF-1. 61 54
19318803 2009
10
PAX5 is expressed in small-cell lung cancer and positively regulates c-Met transcription. 61 54
19139719 2009
11
Monoclonality of composite large cell neuroendocrine carcinoma and mucinous epithelial tumor of the ovary: a case study. 61 54
19047907 2009
12
Frequent expression of glypican-3 in Merkel cell carcinoma: an immunohistochemical study of 55 cases. 54 61
18813128 2009
13
Is nonsmall cell type high-grade neuroendocrine carcinoma of the tubular gastrointestinal tract a distinct disease entity? 54 61
18360283 2008
14
Differential expression of neural-cadherin in pulmonary epithelial tumours. 54 61
18269586 2008
15
Association of malignant insulinoma and type 2 diabetes mellitus: a case report. 61 54
18291348 2008
16
Primary male neuroendocrine adenocarcinoma involving the nipple simulating Merkel cell carcinoma - a diagnostic pitfall. 61 54
18190447 2008
17
Clinical implications of unusual NeuroD and mASH1 expression in a patient with primary large-cell neuroendocrine carcinoma of the duodenum: report of a case. 54 61
18751955 2008
18
Coexpression of c-kit and bcl-2 in small cell carcinoma and large cell neuroendocrine carcinoma of the lung. 54 61
18091382 2007
19
Gastric neuroendocrine carcinoma: clinicopathologic review and immunohistochemical study of E-cadherin and Ki-67 as prognostic markers. 54 61
17066436 2007
20
Medical treatment of gastrinomas. 54 61
17985097 2007
21
Interferon-alpha and somatostatin analog in patients with gastroenteropancreatic neuroendocrine carcinoma: single agent or combination? 54 61
16798833 2007
22
Distinction of pulmonary large cell neuroendocrine carcinoma from small cell lung carcinoma: a morphological, immunohistochemical, and molecular analysis. 61 54
16862075 2006
23
Tumor of the liver (hepatocellular and high grade neuroendocrine carcinoma): a case report and review of the literature. 61 54
16896889 2006
24
[Clinicopathologic characteristics of colorectal neuroendocrine tumor]. 61 54
16929153 2006
25
Composite adenocarcinoma and large cell neuroendocrine carcinoma of the rectum. 61 54
16508780 2006
26
Neuroendocrine features in poorly differentiated endometrioid adenocarcinomas of the endometrium. 54 61
16681768 2006
27
Recent immunohistochemical markers in the differential diagnosis of primary and metastatic carcinomas of the liver. 61 54
16078249 2005
28
CDX2 is a useful marker of intestinal-type differentiation: a tissue microarray-based study of 629 tumors from various sites. 54 61
16119980 2005
29
Cytokeratin 20-positive large cell neuroendocrine carcinoma of the colon. 54 61
15998383 2005
30
Carcinosarcoma of the liver: a case report and review of the literature. 54 61
15913431 2005
31
Metastasis of small cell carcinoma of lung into an ovarian mucinous neoplasm: immunohistochemistry as a useful ancillary technique for diagnosis and classification of rare tumors. 54 61
15722802 2005
32
Duodenal somatostatinoma: clinical and immunohistochemical patterns--difficult differential diagnosis in regard to gangliocytic paraganglioma: report of a case. 54 61
15851380 2005
33
Small cell neuroendocrine carcinomas of the uterine cervix: a histological, immunohistochemical, and molecular genetic study. 61 54
15381906 2004
34
Ovarian non-small cell neuroendocrine carcinoma with paraneoplastic parathyroid hormone-related hypercalcemia. 54 61
15381910 2004
35
Thyroid transcription factor-1, but not p53, is helpful in distinguishing moderately differentiated neuroendocrine carcinoma of the larynx from medullary carcinoma of the thyroid. 54 61
15098009 2004
36
Comparative study of primary mammary small cell carcinoma, carcinoma with endocrine features and invasive ductal carcinoma. 54 61
15010880 2004
37
Small cell neuroendocrine carcinoma of the cervix: outcome and patterns of recurrence. 61 54
15047210 2004
38
hASH1 expression is closely correlated with endocrine phenotype and differentiation extent in pulmonary neuroendocrine tumors. 54 61
14657947 2004
39
The prognostic role of c-kit protein expression in resected large cell neuroendocrine carcinoma of the lung. 54 61
14726070 2004
40
Diagnostic value of microtubule-associated protein-2 in Merkel cell carcinoma. 54 61
14663358 2003
41
Analysis of protein expression and gene mutation of c-kit in colorectal neuroendocrine carcinomas. 61 54
14657715 2003
42
Frequent overexpression of the c-kit protein in large cell neuroendocrine carcinoma of the lung. 54 61
12711118 2003
43
Prognostic implications of neuroendocrine differentiation and hormone production in patients with Stage I nonsmall cell lung carcinoma. 54 61
12733148 2003
44
Diagnostic value of microtubule-associated protein-2 (MAP-2) for neuroendocrine neoplasms. 61 54
12605092 2003
45
Histidine decarboxylase expression as a new sensitive and specific marker for small cell lung carcinoma. 61 54
12527716 2003
46
Neuroendocrine tissue-specific transcription factor, BETA2/NeuroD, in gastric carcinomas: a comparison with chromogranin A and synaptophysin expressions. 61 54
14533935 2003
47
[Intraarterial neoadjuvant chemotherapy with cisplatin effective against neuroendocrine carcinoma of the urinary bladder: a case report]. 61 54
12229180 2002
48
Thyroid transcription factor 1 and cytokeratins 1, 5, 10, 14 (34betaE12) expression in basaloid and large-cell neuroendocrine carcinomas of the lung. 61 54
11567220 2001
49
Histologic and immunophenotypic classification of cervical carcinomas by expression of the p53 homologue p63: a study of 250 cases. 54 61
11381365 2001
50
Primary mesenteric malignant mixed mesodermal (müllerian) tumor with neuroendocrine differentiation. 54 61
11353063 2001

Variations for Neuroendocrine Carcinoma

Copy number variations for Neuroendocrine Carcinoma from CNVD:

7 (show all 16)
# CNVD ID Chromosome Start End Type Gene Symbol CNVD Disease
1 46474 10 81600000 81900000 Gain or loss C10orf57 Neuroendocrine carcinoma
2 46475 10 81600000 81900000 Gain or loss PLAC9 Neuroendocrine carcinoma
3 46476 10 81600000 81900000 Gain or loss SFTPD Neuroendocrine carcinoma
4 98126 16 15400000 16800000 Duplication ABCC1 Neuroendocrine carcinoma
5 98127 16 15400000 16800000 Duplication ABCC6 Neuroendocrine carcinoma
6 98128 16 15400000 16800000 Duplication C16orf45 Neuroendocrine carcinoma
7 98129 16 15400000 16800000 Duplication C16orf63 Neuroendocrine carcinoma
8 98130 16 15400000 16800000 Duplication KIAA0430 Neuroendocrine carcinoma
9 98131 16 15400000 16800000 Duplication MYH11 Neuroendocrine carcinoma
10 98132 16 15400000 16800000 Duplication NDE1 Neuroendocrine carcinoma
11 109503 17 26446120 26728821 Microdeletion NF1 Neuroendocrine carcinoma
12 111157 17 35097918 35138441 Gain HER-2/neu Neuroendocrine carcinoma
13 122931 18 64000000 64040000 Deletion Neuroendocrine carcinoma
14 160839 22 16300000 24300000 Microdeletion Neuroendocrine carcinoma
15 226129 7 55054218 55242525 Gain EGFR Neuroendocrine carcinoma
16 248801 9 137300000 137400000 Duplication C9orf62 Neuroendocrine carcinoma

Expression for Neuroendocrine Carcinoma

Search GEO for disease gene expression data for Neuroendocrine Carcinoma.

Pathways for Neuroendocrine Carcinoma

Pathways related to Neuroendocrine Carcinoma according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 11.89 SYP NKX2-1 NCAM1 ENO2 CALCA
2 11.34 PTEN PDGFRA KIT
3 11.06 PDGFRA NCAM1 KIT
4 10.92 SYP PDGFRA NCAM1 FGFR4 ASCL1
5 10.1 GRP GAST

GO Terms for Neuroendocrine Carcinoma

Cellular components related to Neuroendocrine Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.56 SST MUC1 KIT GRP GAST ENO2
2 extracellular region GO:0005576 9.28 SST PTEN NCAM1 MUC1 GRP GAST

Biological processes related to Neuroendocrine Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 MAPK cascade GO:0000165 9.76 PDGFRA NCAM1 KIT FGFR4
2 positive regulation of kinase activity GO:0033674 9.5 PDGFRA KIT FGFR4
3 positive regulation of phospholipase C activity GO:0010863 9.43 PDGFRA KIT
4 Leydig cell differentiation GO:0033327 9.4 PDGFRA NKX2-1
5 forebrain neuron differentiation GO:0021879 9.37 NKX2-1 ASCL1
6 mast cell chemotaxis GO:0002551 9.26 KIT CHGA
7 positive regulation of phospholipase C-activating G protein-coupled receptor signaling pathway GO:1900738 9.16 GRP CHGA
8 cerebral cortex GABAergic interneuron differentiation GO:0021892 8.96 NKX2-1 ASCL1
9 mast cell cytokine production GO:0032762 8.62 KIT CHGA

Molecular functions related to Neuroendocrine Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 transmembrane receptor protein tyrosine kinase activity GO:0004714 8.8 PDGFRA KIT FGFR4

Sources for Neuroendocrine Carcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....